Analysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Target Price at $25.56

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seventeen research firms that are presently covering the stock, Marketbeat reports. Six research analysts have rated the stock with a hold rating and eleven have issued a buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $25.56.

ACAD has been the subject of a number of recent analyst reports. Citigroup lowered their price target on ACADIA Pharmaceuticals from $30.00 to $23.00 and set a "buy" rating for the company in a research report on Thursday, August 8th. StockNews.com raised shares of ACADIA Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 13th. Cantor Fitzgerald dropped their target price on shares of ACADIA Pharmaceuticals from $37.00 to $28.00 and set an "overweight" rating for the company in a research report on Wednesday, August 7th. Royal Bank of Canada reduced their price target on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an "outperform" rating on the stock in a research report on Wednesday, August 7th. Finally, Needham & Company LLC restated a "buy" rating and issued a $28.00 target price on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th.

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, CFO Mark C. Schneyer sold 9,733 shares of the firm's stock in a transaction on Monday, August 19th. The stock was sold at an average price of $15.28, for a total value of $148,720.24. Following the transaction, the chief financial officer now directly owns 43,735 shares in the company, valued at $668,270.80. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. In related news, CFO Mark C. Schneyer sold 9,733 shares of the firm's stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total value of $148,720.24. Following the transaction, the chief financial officer now owns 43,735 shares of the company's stock, valued at approximately $668,270.80. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Brendan Teehan sold 9,534 shares of the company's stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $15.28, for a total transaction of $145,679.52. Following the sale, the chief operating officer now directly owns 52,177 shares of the company's stock, valued at approximately $797,264.56. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 51,014 shares of company stock worth $779,494. Insiders own 28.30% of the company's stock.

Hedge Funds Weigh In On ACADIA Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. M&G Plc bought a new stake in ACADIA Pharmaceuticals during the 1st quarter valued at approximately $5,622,000. SG Americas Securities LLC lifted its holdings in shares of ACADIA Pharmaceuticals by 246.7% in the first quarter. SG Americas Securities LLC now owns 84,956 shares of the biopharmaceutical company's stock worth $1,571,000 after buying an additional 60,452 shares in the last quarter. Fred Alger Management LLC boosted its position in shares of ACADIA Pharmaceuticals by 19.8% during the second quarter. Fred Alger Management LLC now owns 2,704,439 shares of the biopharmaceutical company's stock worth $43,947,000 after acquiring an additional 446,875 shares during the last quarter. Sei Investments Co. boosted its position in shares of ACADIA Pharmaceuticals by 6.2% during the first quarter. Sei Investments Co. now owns 34,752 shares of the biopharmaceutical company's stock worth $642,000 after acquiring an additional 2,034 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in ACADIA Pharmaceuticals in the 1st quarter valued at $48,000. Hedge funds and other institutional investors own 96.71% of the company's stock.

ACADIA Pharmaceuticals Price Performance

NASDAQ ACAD traded down $0.26 on Wednesday, reaching $17.67. 466,847 shares of the company's stock traded hands, compared to its average volume of 1,680,188. The stock has a market cap of $2.94 billion, a PE ratio of 22.58 and a beta of 0.38. ACADIA Pharmaceuticals has a 12 month low of $14.15 and a 12 month high of $32.59. The stock has a 50-day simple moving average of $15.51 and a 200 day simple moving average of $15.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating the consensus estimate of $0.14 by $0.06. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The company had revenue of $250.40 million for the quarter, compared to analyst estimates of $248.83 million. During the same quarter last year, the firm earned ($0.40) EPS. The firm's quarterly revenue was up 18.3% compared to the same quarter last year. As a group, analysts anticipate that ACADIA Pharmaceuticals will post 0.72 EPS for the current year.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.